| ACE | Angiotensin-converting enzyme |
| ACTH | Adrenocorticotropic hormone |
| AE | Adverse event |
| ARB | Angiotensin receptor blocker |
| ARR | Aldosterone-to-renin ratio |
| ASI | Aldosterone synthase inhibitor |
| AT1R | Angiotensin II type 1 receptor |
| CKD | Chronic kidney disease |
| CYP11B1 | 11β-Hydroxylase |
| CYP11B2 | Aldosterone synthase |
| DBP | Diastolic blood pressure |
| DOC | 11-Deoxycorticosterone |
| eGFR | Estimated glomerular filtration rate |
| ENaC | Epithelial sodium channel |
| HF | Heart failure |
| HFpEF | Heart failure with preserved ejection fraction |
| HFrEF | Heart failure with reduced ejection fraction |
| MRA | Mineralocorticoid receptor antagonist |
| MR | Mineralocorticoid receptor |
| PA | Primary aldosteronism |
| RAAS | Renin–angiotensin–aldosterone system |
| RH | Resistant hypertension |
| SBP | Systolic blood pressure |
| SGLT2 | Sodium–glucose cotransporter 2 |
| StAR | Steroidogenic acute regulatory protein |
| TGF-β | Transforming growth factor-beta |
| UACR | Urinary albumin-to-creatinine ratio |
| UFC | Urinary free cortisol |
| AT1 | Angiotensin II type 1 |
| MR | Mineralocorticoid receptors |
| CTGF | Connective tissue growth factor |
| ARB | Angiotensin receptor blockers |
| MRA | Mineralocorticoid receptor antagonists |